Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
pharmaphorum2d
Pfizer confirms $160bn reverse takeover of Allergan
and re-naming itself Pfizer. The deal is the biggest ever seen in the pharma sector, and also makes it a record-breaking year for the whole sector, which has now seen acquisitions worth over $600 ...
Hosted on MSN15d
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
BioSpace3d
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
devdiscourse10d
Health News Roundup: Executive Orders, Vaccine Warnings, and Medical Acquisitions
The latest health news highlights Trump considering an executive order to protect gas stoves, warnings for GSK's and Pfizer's ...
Benzinga.com4d
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” Pfizer’s CEO ...